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Methods for mapping facilitators and hindrances: Focus group
interviews with main stakeholders and review of existing
documentation.
Implementation Strategy: The Swedish model was chosen for
implementation in Iceland, with the aim of avoiding to reinvent
the wheel for the small and sparsely populated country. It is
assumed that disease pattern is similar in the two countries, and
that population pyramids are sufﬁciently similar for the purpose
of applying Swedish cost-effectiveness data in Iceland. The best
way to use the Swedish model would be to adapt the cost-
effectiveness modeling to the situation in Iceland, i.e. to get ready
reports/models from Sweden, with the possibility of recalculating
the cost-effectiveness on the basis of Icelandic data.
Results: The focus group interviews showed that change man-
agement needs to be applied as regards the civil servants, as they
show a reluctant attitude towards implementing this change. On
the contrary the focus group interviews revealed that the drug
industry has a more positive view of the change, probably inﬂu-
enced by the seemingly good cooperation between the drug
industry and the Pharmaceutical Beneﬁts Board in Sweden
(LFN). Based on the results the health ministers of Iceland and
Sweden signed in June 2008 letter of intent stating that the
Government of Iceland and the Government of Sweden declare
their intention to strengthen and broaden mutual co-operation in
the ﬁeld of pricing and reimbursement of pharmaceuticals. The
Icelandic Medicine Pricing and Reimbursement Committee and
the Pharmaceutical Beneﬁts Board in Sweden (LFN) have started
collaboration on possible dual application on price and reim-
bursements and revaluation of pharmaceutical groups for
reimbursements.
Lessons Learned: Small markets in Europe are facing various
issues regarding pricing and reimbursements of pharmaceuticals
and evaluation from a cost-effectiveness perspective. For reim-
bursement authorities in smaller markets cooperation with lager
organizations is important. The Icelandic Medicine Pricing and
Reimbursement Committee and the Pharmaceutical Beneﬁts
Board in Sweden (LFN) will be starting a pilot project offering
the industry a dual application for price and reimbursement in
Iceland and Sweden. This pilot project will reveal the obstacles
encountered in dual application and how cost effectiveness
reports based on Swedish settings apply to Icelandic settings. If
Icelandic authorities cannot use the reports accompanying appli-
cations in Sweden, an attempt could be made at ﬁnding a con-
stant that could be used as a multiplier for all Swedish cost items,
or results from Sweden could be used without evaluating to what
extent they apply to Iceland, with all the imprecision inherent in
that method.
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OBJECTIVES: Develop a budget impact analysis to present to the
Pharmacy and Therapeutics (P&T) Committee for approval of
paclitaxel protein-bound (paclitaxel-PB) to the institution’s For-
mulary formetastatic breast cancer (MBC). A post-approval study
was performed to assess the accuracy and validity of our model.
METHODS: A pre-approval annual budget impact model for
paclitaxel-PB was developed, and presented to P&T in 2006.
Assumptions regarding paclitaxel-PB’s number of doses per cycle
and median number of cycles per patient were estimated from
published clinical trials and clinicians estimated use. In 2007, a
post-approval economic analysis was conducted to assess the
actual annual budget impact of paclitaxel-PB. All costs were
adjusted to 2007 dollars. RESULTS: Paclitaxel-PB was FDA-
approved forMBC in January 2005. InMay 2006 a budget impact
model was developed for an institutional population of 46 MBC
patients; the $722,935 estimate was presented to the P&T. In
September of 2007, we reviewed all use (excluding investiga-
tional) of paclitaxel-PB from June 2006 through May 2007.
During this time period, we treated 131 patients; of these, 76
(58%) were for MBC, 47 (36%) for metastatic melanoma and
8 (6%) for other indications. We also reviewed charge and
reimbursement data for paclitaxel-PB from June to December
2006. For the MBC population, we had a positive margin, and
reimbursement to charge ratio was 59%. When all indications
were included, the overall reimbursement to charge ratio for
paclitaxel-PB was 56%. Actual budget impact was $757,502.
CONCLUSIONS: Differences were noted between the two
studies. Our pre-approval model included only MBC, and fewer
patients than were actually treated. Although we found more
patients on paclitaxel-PB for both FDA-approved and non FDA-
approved indications, the budget impact was essentially the same.
The major factors driving the difference between pre and post-
approval were actual cost per mg and average dose per patient.
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OBJECTIVES: As mentioned in the ISPOR guidelines for budget
impact analysis, estimating the size of the target population and
possible patient subgroups over time is critical for the determi-
nation of the budget impact. The goal of this study was to
estimate the number of patients with bone metastases (BM)
subsequent to breast cancer (BC) from 1992 to 2020 in the UK.
METHODS: A demographic model was developed to assess the
size of the at-risk population. BC incidence rates were obtained
from the Ofﬁce for National Statistics. Each new incident cohort
of BC was run through a Markov model reﬂecting the progres-
sion of the disease (silent disease, bone and visceral metastatic
disease, death due to BC, other death). Transition probabilities
for the ﬁrst year of interest were obtained from a recent meta-
analysis on the effect of chemotherapy. Treatments launched
since 1992 were identiﬁed and corresponding risk reductions
(obtained from the literature) applied to the baseline transition
probabilities to reﬂect the improved prognosis of women with
BC. National statistics were used to validate the model.
RESULTS: The use of constant, unadjusted transition probabili-
ties resulted in an over-estimation of the number of BC deaths by
21% in 2005. After adjustment of the transition probabilities to
include recent therapeutic advancements, the model predicted
12,575 BC deaths in 2005, while 12,509 had been observed
(0.53% difference). Assuming that the treatment options remain
unchanged and that BC incidence by age remains constant, the
population of women suffering from BM is predicted to reach
50,000 in 2020. CONCLUSIONS: Modelling the disease pro-
gression at the national level allows the validation of absolute
numbers of patients over time using national statistics. Compari-
son of model predictions with historical data shows that the
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